Clinical characteristics of patients who survived 1 year or less vs more than 1 year after SCNSL diagnosis
| Variables . | Survival ≤1 y (N = 50) . | Survival >1 y (N = 18) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (IQR), y | 71 (65-78) | 71 (56-76) | .36 |
| Age at SCNSL, median (IQR), y | 71 (66-79) | 74 (58-77) | .46 |
| Time to SCNSL, median (IQR), mo | 7.8 (5.5-15) | 19.2 (7-37) | .037 |
| Type of SCNSL, n (%) | .15 | ||
| Isolated SCNSL | 32 (64.0) | 15 (83.3) | |
| Concomitant systemic relapse | 18 (36.0) | 3 (16.7) | |
| Site of SCNSL, n (%) | 1 | ||
| Parenchymal | 33 (66.0) | 12 (66.7) | |
| Nonparenchymal | 17 (34.0) | 6 (33.3) | |
| CNS-IPI, n (%) | <.001 | ||
| 0-1 | 3 (6) | 8 (44.4) | |
| 2-3 | 15 (30) | 5 (27.8) | |
| 4-6 | 32 (64.0) | 5 (27.8) | |
| Age at diagnosis >60, n (%) | .196 | ||
| Yes | 41 (82) | 12 (67) | |
| No | 9 (18) | 6 (33) | |
| ECOG PS at diagnosis >1, n (%) | .027 | ||
| Yes | 22 (44) | 2 (11) | |
| No | 28 (56) | 16 (89) | |
| Stage III-IV at diagnosis, n (%) | .089 | ||
| Yes | 43 (86) | 12 (67) | |
| No | 7 (14) | 6 (33) | |
| Baseline LDH elevated, n (%) | .009 | ||
| Yes | 42 (84) | 9 (50) | |
| No | 8 (16) | 9 (50) | |
| EN sites at diagnosis >1, n (%) | .007 | ||
| Yes | 33 (66) | 5 (28) | |
| No | 17 (34) | 13 (72) | |
| Kidney/adrenal gland involvement, n (%) | .205 | ||
| Yes | 14 (28) | 2 (11) | |
| No | 36 (72) | 16 (89) | |
| CNS prophylaxis, n (%) | .17 | ||
| Yes | 24 (48.0) | 5 (27.8) | |
| No | 26 (52.0) | 13 (72.2) | |
| SCNSL treatment, n (%) | .08 | ||
| Yes | 27 (81.8) | 17 (100) | |
| No | 6 (18.2) | 0 (0) | |
| Missing | 17 | 1 |
| Variables . | Survival ≤1 y (N = 50) . | Survival >1 y (N = 18) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (IQR), y | 71 (65-78) | 71 (56-76) | .36 |
| Age at SCNSL, median (IQR), y | 71 (66-79) | 74 (58-77) | .46 |
| Time to SCNSL, median (IQR), mo | 7.8 (5.5-15) | 19.2 (7-37) | .037 |
| Type of SCNSL, n (%) | .15 | ||
| Isolated SCNSL | 32 (64.0) | 15 (83.3) | |
| Concomitant systemic relapse | 18 (36.0) | 3 (16.7) | |
| Site of SCNSL, n (%) | 1 | ||
| Parenchymal | 33 (66.0) | 12 (66.7) | |
| Nonparenchymal | 17 (34.0) | 6 (33.3) | |
| CNS-IPI, n (%) | <.001 | ||
| 0-1 | 3 (6) | 8 (44.4) | |
| 2-3 | 15 (30) | 5 (27.8) | |
| 4-6 | 32 (64.0) | 5 (27.8) | |
| Age at diagnosis >60, n (%) | .196 | ||
| Yes | 41 (82) | 12 (67) | |
| No | 9 (18) | 6 (33) | |
| ECOG PS at diagnosis >1, n (%) | .027 | ||
| Yes | 22 (44) | 2 (11) | |
| No | 28 (56) | 16 (89) | |
| Stage III-IV at diagnosis, n (%) | .089 | ||
| Yes | 43 (86) | 12 (67) | |
| No | 7 (14) | 6 (33) | |
| Baseline LDH elevated, n (%) | .009 | ||
| Yes | 42 (84) | 9 (50) | |
| No | 8 (16) | 9 (50) | |
| EN sites at diagnosis >1, n (%) | .007 | ||
| Yes | 33 (66) | 5 (28) | |
| No | 17 (34) | 13 (72) | |
| Kidney/adrenal gland involvement, n (%) | .205 | ||
| Yes | 14 (28) | 2 (11) | |
| No | 36 (72) | 16 (89) | |
| CNS prophylaxis, n (%) | .17 | ||
| Yes | 24 (48.0) | 5 (27.8) | |
| No | 26 (52.0) | 13 (72.2) | |
| SCNSL treatment, n (%) | .08 | ||
| Yes | 27 (81.8) | 17 (100) | |
| No | 6 (18.2) | 0 (0) | |
| Missing | 17 | 1 |
Boldface values represent statistically significant results.